Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Accumulated Expenses over the past 12 years, most recently at $62.0 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $62.0 million for Q4 2025, up 35.6% from a year ago — trailing twelve months through Dec 2025 was $62.0 million (up 35.6% YoY), and the annual figure for FY2025 was $62.0 million, up 35.6%.
  • Accumulated Expenses for Q4 2025 was $62.0 million at Viridian Therapeutics, Inc.\DE, up from $40.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for VRDN hit a ceiling of $62.0 million in Q4 2025 and a floor of $10.3 million in Q3 2021.
  • Median Accumulated Expenses over the past 5 years was $22.3 million (2023), compared with a mean of $24.9 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 368.54% in 2021 and later dropped 9.43% in 2022.
  • Viridian Therapeutics, Inc.\DE's Accumulated Expenses stood at $11.0 million in 2021, then soared by 70.87% to $18.8 million in 2022, then rose by 28.05% to $24.1 million in 2023, then skyrocketed by 89.69% to $45.7 million in 2024, then soared by 35.6% to $62.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $62.0 million (Q4 2025), $40.6 million (Q3 2025), and $35.3 million (Q2 2025) per Business Quant data.